[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Definium Therapeutics Inc (DFTX)

Definium Therapeutics Inc (DFTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,411,695
  • Shares Outstanding, K 99,698
  • Annual Sales, $ 0 K
  • Annual Income, $ -183,790 K
  • EBIT $ -193 M
  • EBITDA $ -195 M
  • 60-Month Beta 2.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.41

Options Overview Details

View History
  • Implied Volatility 143.86% (+5.83%)
  • Historical Volatility 54.23%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 143.86% on 05/29/26
  • IV Low 62.19% on 04/15/26
  • Expected Move (DTE 19) 5.40 (22.31%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 1,708
  • Volume Avg (30-Day) 1,199
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 63,772
  • Open Int (30-Day) 60,207
  • Expected Range 18.79 to 29.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.54
  • Number of Estimates 6
  • High Estimate $-0.49
  • Low Estimate $-0.58
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.33 +25.14%
on 05/19/26
24.29 -0.41%
on 05/29/26
+3.70 (+18.06%)
since 04/29/26
3-Month
16.55 +46.16%
on 03/03/26
26.25 -7.85%
on 04/20/26
+6.74 (+38.62%)
since 02/27/26
52-Week
6.34 +281.55%
on 06/23/25
26.25 -7.85%
on 04/20/26
+17.04 (+238.32%)
since 05/28/25

Most Recent Stories

More News
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program

Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data...

DFTX : 24.19 (+3.02%)
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Q1 Earnings Call Highlights

Definium Therapeutics (NASDAQ:DFTX) reported first-quarter 2026 financial results and outlined a series of near-term clinical milestones for its lead candidate, DT120 ODT, during a conference call held...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in...

DFTX : 24.19 (+3.02%)
Definium Therapeutics Prepares to Explain Why the Next Trial Will Be Different

Barchart Research What to Expect from DFTX Earnings DFTX Generated May 6, 2026 Current Price $23.42 EPS Estimate $$-0.47 Consensus Rating Strong Buy Average Move 4.80% Definium Therapeutics Prepares to...

DFTX : 24.19 (+3.02%)
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 24.19 (+3.02%)
These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

CMPS : 13.06 (+9.56%)
PSIL : 21.72 (+1.21%)
ATAI : 4.53 (+2.72%)
DFTX : 24.19 (+3.02%)
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with...

DFTX : 24.19 (+3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK....

See More

Key Turning Points

3rd Resistance Point 25.54
2nd Resistance Point 24.92
1st Resistance Point 24.55
Last Price 24.19
1st Support Level 23.56
2nd Support Level 22.94
3rd Support Level 22.57

See More

52-Week High 26.25
Last Price 24.19
Fibonacci 61.8% 18.64
Fibonacci 50% 16.30
Fibonacci 38.2% 13.95
52-Week Low 6.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.